Thesis

Protalix BioTherapeutics filed its 10-K on March 18, 2026. Note 16(b) of the audited financial statements reads: "The Company became entitled to a regulatory milestone payment of $25.0 million from Chiesi in connection with the EC's approval of the E4W dosing regimen." This is not guidance, not a probability — it is a legally triggered receivable, signed by PricewaterhouseCoopers Israel. The stock closed down 19% on the same day.

At $2.25 and 80.4M shares, PLX trades at $181M market cap. The $25M milestone is 13.8% of market cap and arrives within 60-90 days. Back-solving from $2.25, the market is embedding a 52% probability of the bear case. We assess 20%. That 32-point gap is the trade.

The thesis is two-layered: a near-term confirmed cash event (90 days, high conviction), and a second act in EU commercial recovery where an uncontested E4W dosing moat has no competitor in sight (12-24 months, medium conviction). The pipeline story (PRX-115 for refractory gout) is a drag, not an asset. The Israel-Iran manufacturing risk is real but systematic — covered elsewhere, not unique to PLX.

The Milestone

The EC approved Elfabrio's every-4-weeks (E4W) dosing regimen for Fabry disease patients stable on enzyme replacement therapy on March 5/9, 2026. This triggered a $25M payment owed by Chiesi to PLX under the Ex-US Collaboration Agreement.

The milestone is:

• Confirmed in audited financials — not a press release claim, not guidance. It passed PwC's audit scope.
• Chiesi credit risk: negligible — Chiesi is a multi-billion-dollar Italian pharma company. The only scenario where this $25M doesn't arrive is Chiesi bankruptcy, which is not indicated.
• Additive to a clean balance sheet — PLX had $30.3M in cash and deposits at year-end with no debt (notes fully repaid September 2024). Post-milestone: ≈$55M effective liquidity. The company guided "at least 12 months" of runway before this payment.

The payment timing is not specified in the disclosed agreement terms. 8-K receipt announcement expected April–May 2026.

The Mispricing

At $2.25, the market is pricing PLX as if there's a 52% chance the business deteriorates to ≈$1.10 (adjusted NAV, wind-down scenario). That requires: structural Chiesi revenue decline, Israel manufacturing disruption, no US E4W filing, and an equity raise — simultaneously. We put that probability at 20%.

The $2.25 price corresponds to 3.4x FY2025 revenue. Comparable commercial-stage rare disease companies trade at 4-6x revenue. At 4x (the conservative floor for a company with uncontested EU moat, no debt, and a confirmed near-term cash receipt): $2.63/share. Current price is 14% below that before factoring in the milestone, the US E4W option, or EU E4W uptake.

At 7x gross profit ($25.7M), fair value is $2.24/share — essentially where the stock is trading. The market is pricing zero optionality on everything: milestone receipt, EU commercial recovery, and $740M of remaining US milestone potential. All of it at zero.

The FY2025 net loss of $(6.6M) likely drove the sell-off. But the loss is explainable: Chiesi product revenues fell 23% ($29.3M → $22.5M) on ordering timing variability, and R&D jumped 51% to $19.6M from the RELEASE Phase 2 study startup. Structural operating burn ex-working-capital builds was approximately $(1.6M). That is not a distressed business.

The EU Moat

E4W is a real competitive advantage in Europe. Current standard of care — Sanofi's Fabrazyme and Takeda's Replagal — requires every-2-weeks infusions. Elfabrio E4W cuts infusion frequency in half for patients stable on ERT.

Cross-ticker verification confirmed no competitor is catching up:

• Sanofi (SNY): Zero E4W development program for Fabrazyme. More importantly, venglustat — the only credible oral therapy challenger to Fabry ERT — failed its Phase 3 primary endpoint (PERIDOT study), disclosed in the SNY 20-F filed 2026-02-17. The only pipeline threat to ERT market share is effectively dead.
• Takeda (TAK): Zero E4W development program for Replagal. Replagal isn't even approved in the US.

The moat has one important limitation: it is EU-only. FDA still requires 1mg/kg E2W dosing in the US. The EC approval required re-examination after an initial CHMP rejection, suggesting the data was marginally sufficient. Eligible patients are limited to those already "stable on ERT" — not treatment-naive. EU moat is real; global moat is overstated.

The larger prize — $740M in remaining milestone potential under the US Agreement versus $270M Ex-US — requires Chiesi to file a supplemental BLA with FDA. No filing has been initiated. At 55% probability by end of 2027, the expected value of that option alone approaches current market cap.

The Drag

PRX-115 is burning approximately $7M+ per year in R&D. It is losing the race it entered.

Sobi's NASP (Pegadriscase co-administered with nanoencapsulated sirolimus) has a PDUFA date of June 27, 2026, for uncontrolled/refractory gout. Phase 3 DISSOLVE I & II both met primary endpoints (43-51% response rates). Fast Track designation. NASP's technical differentiation is meaningful: prior PEGylated uricase therapies (Krystexxa/pegloticase) lost efficacy because patients developed anti-drug antibodies; NASP co-administers sirolimus to suppress the immune response. PRX-115 does not appear to include this component.

Sobi also acquired Arthrosi Therapeutics in December 2025 for $950M upfront, adding an oral URAT1 inhibitor (pozdeutinurad, two fully-recruited Phase 3 trials) to build a comprehensive gout franchise. When PRX-115 eventually files — 2028 at the earliest — it faces NASP with two or more years of commercial data and potentially an approved oral alternative targeting the adjacent population.

PRX-115 has option value if the data surprises or if a differentiated mechanism emerges. But it should not be counted as a positive contributor to near-term thesis. It is a cash drag attached to a diminishing competitive position.

Israel-Iran Risk

PLX manufactures Elfabrio and taliglucerase alfa exclusively in Carmiel, Israel. On February 28, 2026, US and Israeli militaries commenced air-based campaigns in Iran, resulting in increased missile attacks on Israel. PLX disclosed this in the 10-K risk factors.

This risk is real but systematic. Cross-ticker work found 147 companies across sectors disclosing the same risk in Q4 2025 earnings calls. More importantly, Ituran (Israel-based, vehicle tracking) reported an actual 12-day economic standstill and 6% product revenue decline from a prior Israel-Iran engagement. The tail has already materialized at a peer company.

PLX's mitigants: Carmiel facility holds "essential enterprise" designation, and drug substance is stored at multiple locations inside and outside Israel. No operational impact as of filing.

For portfolio purposes, this is a country-level factor that should be managed at the sleeve level, not a stock-level LR adjustment for PLX in isolation.

Forward EV

Three scenarios, probability-weighted:

EV = $3.90 vs $2.25 current = +73%

EV stays positive against $2.25 unless bear probability exceeds 50%. We're at 20%.

90-day trade (milestone only): EV = (0.80 × +20%) + (0.20 × -18%) = +12.4% in 90 days, ≈50% annualized. This is the floor. EU recovery and US option attached for free.

Entry: $2.00–$2.40 (current level). RSI 28.7. CEO bought 56,000 shares at $1.81 in December — below current even after the drop. Only one analyst covers this name (HC Wainwright, $11-12 PT).

Stop: Milestone not received by July 31, 2026 — thesis break. Or Chiesi Q2 2026 revenues show continued deterioration, not normalization.

What Could Break This

The -19% drop on confirmation day is the unresolved question. If it's thin float + FY2025 loss headline + sector weakness (XBI was down), this is the entry. If it's informed selling reflecting something not in the 10-K — a Carmiel disruption, a Chiesi relationship issue — this is a trap. This question must be answered before full position sizing, not after.

Chiesi revenue opacity. PLX sees only bulk supply revenues; Chiesi controls patient acquisition. The 23% decline in FY2025 is characterized as ordering variability. If Q2 2026 earnings show further erosion, the base case breaks.

Israel operational disruption. A weeks-long Carmiel shutdown would stop product delivery and revenue. Watch 8-K filings.

Timing

Now — March 18, 2026     Entry window. RSI 28.7, max mispricing.
April–May 2026           $25M receipt 8-K. Stock re-rates. Entry before this is the trade.
June 27, 2026            Sobi NASP PDUFA. If approved, may create narrative dip on PRX-115
                         confusion. Elfabrio thesis unaffected. Buy any Fabry/gout conflation.
August 2026              Q2 earnings. First diagnostic: is Chiesi revenue normalizing?
                         Yes → add. No → question base case.
2026–2027                US E4W sBLA announcement if Chiesi files. Major re-rate to $5–7.

Evidence